Multi-Drug Resistant Bacteria Found on International Space Station (ISS)

Multi-Drug Resistant Bacteria Found on International Space Station (ISS)

17-06-2024

Scientists from the Indian Institute of Technology Madras (IIT-M) and NASA's Jet Propulsion Laboratory (JPL) collaborated to study the behaviour of multi-drug-resistant pathogens (Enterobacter Bugandensis) aboard the International Space Station (ISS).

About Enterobacter Bugandensis:

  1. Enterobacter bugandensis is a relatively novel species within the Enterobacter genus.
  2. Discovered in 2013, it was isolated from cases of bloodstream infections in Uganda.

Key Characteristics:

  1. Morphology: Gram-negative, rod-shaped bacterium.
  2. Habitat: Found in various environments, including soil, water, and the gastrointestinal tracts of animals and humans, similar to other Enterobacter species.
  3. Pathogenicity: Primarily affects immunocompromised individuals, causing infections such as bloodstream infections, respiratory infections, urinary tract infections, and wound infections.
  4. Resistance: E. bugandensis exhibits resistance to multiple antibiotics, making treatment challenging.
    • Resistance mechanisms include beta-lactamase production, efflux pumps, and mutations that reduce drug uptake.

Multi-drug-Resistant Pathogens:

  1. Definition: Multi-drug-resistant (MDR) pathogens are microorganisms that have developed resistance to several antimicrobial agents, usually three or more antimicrobial categories.
  2. Types: MDR can occur in various microorganisms, including bacteria, viruses, and parasites.

Antibiotic Resistance:

  1. Definition: Antibiotic resistance is the ability of bacteria to survive exposure to antibiotics that would normally kill or inhibit their growth.
  2. Significance: Antibiotic resistance poses a significant global health concern.

Must Check: Best IAS Coaching In Delhi

 

 

Prime Minister's Inauguration of Projects in Amaravati, Andhra Pradesh

Government of Karnataka Notifies Hesaraghatta Grassland Conservation Reserve

Cancer Patients in UK to Receive Immunotherapy Drugs via Single Injection for Faster Treatment